ESMO Open

A randomized Ph3 clinical trial of weekly vs tri-weekly cisplatin-based CRT for LA cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study in @ESMO_Open.No survival differences, better tolerability and QoL for tri-weekly administration. esmoopen.com/article/S2059-…

Ph3 trial of infigratinib vs gem/cis in advanced CCA with FGFR2 fusion/rearrangement: results & reflections on early termination of PROOF 301 in @ESMO_Open. 48/300 randomized pts in >3yrs. New frameworks needed to assess therapies in ultra-rare tumors. esmoopen.com/article/S2059-…

TBCRC 035: randomized ph II pharmacodynamic study of standard and reduced-dose palbociclib with ET in HR+ previously treated metastatic BC in @ESMO_Open. Lower dose of palbociclib may reduce severe neutropenia without compromising molecular response. esmoopen.com/article/S2059-…

ctDNA clearance may serve as a promising predictor of treatment response—not only in neoadjuvant chemotherapy, but also in neoadjuvant endocrine therapy. As MRD assays continue to evolve and our therapeutic strategies advance, the potential to refine risk stratification and personalize care in early breast cancer keeps expanding. The development of liquid biopsy–guided decision-making is just getting started. @ESMO_Open esmoopen.com/article/S2059-…

Pleased to share analysis of early endpoints in KEYNOTE585 @myESMO @ESMO_Open. pCR, mPR, and downstaging showed associations with favorable EFS and OS in gastric/GEJ adenocarcinoma treated with perioperative pembro+chemo. Further validation is warranted. sciencedirect.com/science/articl…

👉How do we combine #TKIs with various forms of #radiotherapy in #NSCLC? When should we interrupt or modify their dose? 💡Just out in @ESMO_Open a collaborative effort between @myESMO and @estro with recommendations for #EGFR, #ALK and #BRAF/MEK inhinitors Happy to have contributed to this practical guide for clinicians Link to the article: kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2… #LCSM @IASLC @ASCO @OncoAlert @OncBrothers @oncodaily @MedscapeOnc @VJOncology @Peerview @EGFRResisters @EgfrUk @EGFRmNSCLC @YoungLungCancer @ALKPositiveinc

PFS2 as a surrogate endpoint for OS in breast cancer randomized controlled clinical trials in @ESMO_Open. Context-dependent association, stronger association with higher PFS2 maturity and OS information fraction. esmoopen.com/article/S2059-…

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors in @ESMO_Open. Evidence-based consensus statements providing guidance on the safety of combining RT with EGFR, ALK, or BRAF/MEK inhibitors. esmoopen.com/article/S2059-…

A novel BRCAm classification system reveals differential responses to PARP inhibition and prognostic outcomes in eOC: a multicenter study in @ESMO_Open. New BRCA1m classification system identifies superior PARPi response in DBD/DBD-BRCT region. esmoopen.com/article/S2059-…

ctDNA in neoadjuvant endocrine therapy for early BC in @ESMO_Open. ctDNA detection before & after neoadjuvant endocrine therapy predicts tumor burden & long-term recurrence risk. Tissue-free ctDNA assays may guide surgery & treatment decisions! esmoopen.com/article/S2059-…

Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced NSCLC in @ESMO_Open. Greater microbiota diversity associated with CD8+TILs & better outcomes with dual ICIs but not chemo+dual ICIs. esmoopen.com/article/S2059-…

Global advances and future directions in lung cancer care: expert consensus and strategic priorities in @ESMO_Open. Important advances but global disparities, limited trial access, & implementation challenges still hinder progress. esmoopen.com/article/S2059-…

Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for irAEs in NSCLC in @ESMO_Open. High steroid peak dose associated with reduced survival, but not cumulative dose/2nd line immunesuppression. esmoopen.com/article/S2059-…

A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers in @ESMO_Open. Beyond “one-size-fits-all” approach to improve precision medicine in SGC in a potentially cost-effective way. esmoopen.com/article/S2059-…

In non-metastatic TN-IBC, neoadjuvant chemo + pembrolizumab achieved a 31.7% pCR—lower than expected despite improvement vs historical chemo alone (18%). 94% had surgery; 6.4% progressed during neoadjuvant tx. Open esmoopen.com/article/S2059-…

@ESMO_Open important RWD - as well as outcome for N1 disease. Missed opportunity to improve outcome. @OncoAlert

Exploring the treatment gap and outcome risks in patients with node+, high-risk, HR+, HER2- early BC: analyses of RW data in @ESMO_Open. Only 40% of eligible pts received adj abemaciclib. Eligible not treated: similar TNBC recurrence/mortality risk. esmoopen.com/article/S2059-…

A Ph IV prospective study of efficacy&safety of ribociclib+letrozole as 1L therapy in older women (≥70 years) with HR+ HER2- advanced BC: the RibOB study in @ESMO_Open. Effective therapy in elderlies, frequent dose reductions/early discontinuations. esmoopen.com/article/S2059-…

Declining research interest among oncology residents: insights into the academic career from a nationwide longitudinal study in France in @ESMO_Open. 16% decline in motivation research over 4 years. Main barriers: lack of mentorship, time & funding. esmoopen.com/article/S2059-…

RW outcomes vs clinical trial results of 1L immunotherapy with/without chemotherapy in pts with metastatic NSCLC: the CORRELATE study in @ESMO Open. Retrospective study showing inferior RW outcomes despite using clinical trial eligibility criteria. esmoopen.com/article/S2059-…